Pharmacotherapy in Stress and Mixed Incontinence

Slides:

Advertisements

Similar presentations

Pascal Rischmann European Urology Supplements

Advertisements

Female Urinary Incontinence in the West of Turkey: Prevalence, Risk Factors and Impact on Quality of Life Izzet Kocak, Pinar Okyay, Mehmet Dundar, Haluk.

Achieving the Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management Michael O’Leary European Urology Supplements

Fred Saad European Urology Supplements

Management of Acute and Chronic Retention in Men

Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Steven A. Kaplan,

Volume 64, Issue 4, Pages (October 2013)

Volume 45, Issue 4, Pages (April 2004)

Volume 57, Issue 5, Pages (May 2010)

Martin C. Michel European Urology Supplements

Bladder Cancer: A Major Public Health Issue

Volume 50, Issue 4, Pages (October 2006)

Back to the Future: Introduction and Conclusions

Volume 56, Issue 3, Pages (September 2009)

Volume 43, Issue 4, Pages (April 2003)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Volume 64, Issue 4, Pages (October 2013)

A Novel Treatment of Premature Ejaculation

Counselling the Prostate Cancer Patient

Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old P. Perrin,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

An Update of Current Practice in Hypospadias Surgery

The Inside-Out Transobturator Male Sling for the Surgical Treatment of Stress Urinary Incontinence After Radical Prostatectomy: Midterm Results of a Single-Center.

Richard C. Harkaway European Urology Supplements

Volume 51, Issue 1, Pages (January 2007)

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Philip Toozs-Hobson, Pallavi Latthe European Urology Supplements

Ian Milsom European Urology Supplements

The Importance of Testosterone Control in Prostate Cancer

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Neal Shore European Urology Supplements

When to Treat the Prostate, the Bladder, or Both?

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? François Desgrandchamps European Urology.

Christian Stief European Urology Supplements

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Ureteropelvic Junction Obstruction

Emmanuel Chartier-Kastler, Kate Davidson European Urology Supplements

A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC.

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Who Forms Stones and Why?

Martin Michel, Jean de la Rosette European Urology Supplements

Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer P. Mongiat-Artus, P. Teillac

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

The European Online Sexual Survey (EOSS): Pan-European Perspectives on the Impact of Premature Ejaculation and Treatment-Seeking Behavior John Dean

Improving Flexibility and Quality of Life for Your Patients: A Must?

The Burden of Stress Urinary Incontinence

Profile of Silodosin European Urology Supplements

New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men

Epidemiology, Pathogenesis, and Pathophysiology of Urolithiasis

The Benefits of Dual Inhibition of 5α Reductase

The Impact of Tamsulosin Oral Controlled Absorption System (OCAS) on Nocturia and the Quality of Sleep: Preliminary Results of a Pilot Study Bob Djavan,

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Testim® Gel: Review of Clinical Data

Cardiovascular Safety of Tamsulosin Modified Release in the Fasted and Fed State in Elderly Healthy Subjects Martin C. Michel, Cees Korstanje, Walter.

C.G Roehrborn, T McNicholas European Urology Supplements

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Counselling of the Prostate Cancer Patient as a Whole Person

Joaquim Bellmunt European Urology Supplements

Classification of Mixed Incontinence

Economic and Social Impact of OAB

The Impact of Premature Ejaculation on Partners and Relationships

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

Diagnosis and Management of Cryptorchidism

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Michael Marberger European Urology Supplements

Presentation transcript:

Pharmacotherapy in Stress and Mixed Incontinence Linda Cardozo European Urology Supplements Volume 5, Issue 16, Pages 854-859 (October 2006) DOI: 10.1016/j.eursup.2006.07.003 Copyright © 2006 Terms and Conditions

Fig. 1 Initial management of urinary incontinence in women (algorithm/International Continence Society, Monaco, 2004). European Urology Supplements 2006 5, 854-859DOI: (10.1016/j.eursup.2006.07.003) Copyright © 2006 Terms and Conditions

Fig. 2 Duloxetine: decrease in IEF (12 wk). IEF=incontinence episode frequency. European Urology Supplements 2006 5, 854-859DOI: (10.1016/j.eursup.2006.07.003) Copyright © 2006 Terms and Conditions

Fig. 3 Duloxetine: Improvement in Incontinence Quality of Life (I-QOL) questionnaire scores at 12 wk. ITT=intention to treat. European Urology Supplements 2006 5, 854-859DOI: (10.1016/j.eursup.2006.07.003) Copyright © 2006 Terms and Conditions

Fig. 4 Duloxetine: Treatment-emergent adverse events: nausea. European Urology Supplements 2006 5, 854-859DOI: (10.1016/j.eursup.2006.07.003) Copyright © 2006 Terms and Conditions